Armata Pharmaceuticals

ARMP

Market cap $107M

Overview Fund Activity

2.94 USD

-0.02

0.68%

At close Updated Sep 12, 4:00 PM EDT

1 day

-0.68%

5 days

-0.68%

1 month

19.51%

3 months

46.27%

6 months

55.56%

Year to date

50.77%

1 year

33.64%

5 years

-15.76%

10 years

-99.7%

About: Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Employees: 75

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

29% more capital invested

Capital invested by funds: $1.08M [Q1] → $1.39M (+$313K) [Q2]

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

12% more funds holding

Funds holding: 25 [Q1] → 28 (+3) [Q2]

0.02% less ownership

Funds ownership: 2.05% [Q1] → 2.03% (-0.02%) [Q2]

See Fund Rankings

Financial journalist opinion

Based on 4 articles about ARMP published over the past 30 days

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Describes the structure of phage Pa223, which is included in Armata's multi-phage anti-Pseudomonas clinical candidate, AP-PA02 LOS ANGELES , Sept. 8, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in the Journal of Molecular Biology (JMB).

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

LOS ANGELES , Sept. 4, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D.

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Zacks Investment Research

All You Need to Know About Armata Pharmaceuticals (ARMP) Rating Upgrade to Buy

Armata Pharmaceuticals (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Armata Pharmaceuticals (ARMP) Rating Upgrade to Buy

Zacks Investment Research

Is Armata Pharmaceuticals (ARMP) Outperforming Other Medical Stocks This Year?

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Avadel (AVDL) have performed compared to their sector so far this year.

Is Armata Pharmaceuticals (ARMP) Outperforming Other Medical Stocks This Year?

Zacks Investment Research

Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates

Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.65 per share a year ago.

Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS ANGELES , Aug. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2025, and provided a corporate update. Second Quarter 2025 and Recent Developments: On August 11, 2025, entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc., Armata's largest shareholder, for a loan of $15.0 million that will mature on January 11, 2029 Proceeds from the new financing transaction will be used to continue to advance development of Armata's lead Staphylococcus aureus ("S.

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Zacks Investment Research

ARMP Soars 72% in a Month Following Infectious Disease Study Success

Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.

ARMP Soars 72% in a Month Following Infectious Disease Study Success

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met AP-SA02 arm significantly improved clinical outcomes and prevented relapse compared to best available antibiotic therapy No treatment-related serious adverse events were observed with repetitive intravenous dosing LOS ANGELES , May 19, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced positive topline results from its Phase 1b/2a diSArm trial which evaluated AP-SA02, a novel intravenous ("IV") administered multi-phage therapeutic for the treatment of S taphylococcus aureus ("S. aureus") bacteremia ("SAB"), in the intent-to-treat ("ITT") population.

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

Zacks Investment Research

Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates

Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.69 per share a year ago.

Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

LOS ANGELES , May 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2025, and provided a corporate update. First Quarter 2025 and Recent Developments: Anticipating announcement of topline results from Phase 1b/2a diSArm study of intravenous AP-SA02 as a potential treatment for Staphylococcus aureus ("S.

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

See News Rankings

Charts implemented using Lightweight Charts™